Drug updated on 11/15/2023

Dosage FormCapsule (oral: 0.23 mg, 0.46 mg, 0.92 mg)
Drug ClassSphingosine 1-phosphate receptor modulators
Ongoing and Completed StudiesClinicalTrials.gov


  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
  • For treating moderately to severely active ulcerative colitis (UC) in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Zeposia (ozanimod) Prescribing Information.2022Celgene Corporation, Summit, NJ

Systematic Reviews / Meta-Analyses